Anisodine Hydrobromide Efficacy in Acute Stroke Patients, 2018-2021

A multicenter observational cohort study conducted from April 2018 to December 2021 evaluated the efficacy and safety of anisodine hydrobromide injection for acute ischemic stroke. The study included 4,179 patients, with 2,120 receiving the treatment and 2,059 receiving best medical treatment, and tracked outcomes over 90 days. The dataset was authored by Tianxiang Lan and is licensed under CC-BY-4.0.

Use Cases

• Compare functional outcomes between treatment groups based on modified Rankin Scale scores.
• Analyze safety profiles based on reported adverse events like hemorrhagic transformation.
• Model treatment efficacy using multivariable logistic regression and inverse probability of treatment weighting methods.
• Assess neurological improvement based on changes in National Institutes of Health Stroke Scale scores.

Strengths

• Includes 4,179 patient records from a multicenter study.
• Provides 90-day follow-up data for longitudinal outcome assessment.
• Uses advanced statistical methods like multivariable logistic regression and inverse probability of treatment weighting.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the study conducted in China.

Provenance

Source

figshare

Collection Method

Multicenter, real-world observational cohort study.

Time Range

April 2018 to December 2021

Freshness

Last updated 2026-05-21 05:42:32; freshness should be verified.

Geography

China